Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$75.57 USD

75.57
8,825,251

+0.57 (0.76%)

Updated May 31, 2024 03:59 PM ET

After-Market: $75.97 +0.40 (0.53%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Boston Scientific's Resonate Devices Boost Cardiac Rhythm Arm

Boston Scientific (BSX) is consistently strengthening its Cardiac Rhythm Management segment.

    Medtronic (MDT) Initiates Study on CoreValve Evolut PRO TAVI

    Medtronic (MDT) to initiate FORWARD PRO Clinical Study for evaluating the safety standards of self-expanding TAVI system over longer-term.

      Boston Scientific MultiSENSE Study on HeartLogic Positive

      Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.

        Boston Scientific Grows on Innovation, Buyouts Amid Woes

        While unfavorable foreign exchange continues to raise concerns, Boston Scientific (BSX) stands steadily on growth track with Symetis acquisition and FDA-approved products.

          Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm

          Abbott Laboratories' (ABT) receipt of FDA approval for its Full MagLev HeartMate 3 LVAD strengthens one of its major business segments.

            Boston Scientific (BSX) Tops Q2 Earnings & Sales, View Up

            Boston Scientific's (BSX) Q2 results gain on balanced segmental growth. Currency remains a dampener though.

              Boston Scientific (BSX) Exceeds Q2 Earnings, Sales Estimates

              Boston Scientific (BSX) rides high on acquisitions and FDA approvals.

                Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More

                The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.

                  FDA Approval Widens Medtronic's (MDT) TAVR Platform Reach

                  Medtronic plc (MDT), a well established player in the medical technology, services and solutions space, recently announced FDA approval for the extended use of its self-expanding CoreValve Evolut transcatheter aortic valve replacement (TAVR) platform.

                    Medtronic (MDT) Launches Resolute Onyx DES Device in Japan

                    Medtronic plc (MDT), a leading global player in medical technology, services and solutions, is set to make another encouraging move with respect to its highest revenue grossing Cardiovascular segment.

                      Boston Scientific Rides on New Growth Plans amid Headwinds

                      On Jun 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

                        Brian Hamilton headshot

                        Top Stock Reports for Halliburton, Boston Scientific & Anheuser-Busch

                        Today's Research Daily features new research reports on 16 major stocks, including Halliburton (HAL), Boston Scientific (BSX), and Anheuser-Busch (BUD).

                          Boston Scientific Wins CE Mark for Vercise Gevia DBS System (revised)

                          Generally, DBS therapy is a surgical procedure of placing a device that stimulates specific areas in the brain using electrical signals.

                            Boston Scientific Wins CE Mark for Vercise Gevia DBS System

                            Boston Scientific Corporation (BSX) recently won CE mark for its Vercise Gevia Deep Brain Stimulation (DBS) System.

                              Boston Scientific (BSX) Up 4.4% Since Earnings Report: Can It Continue?

                              Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                Boston Scientific Trades Up on Strong Q1 amid Recall Issues

                                On May 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

                                  Boston Scientific (BSX) BT Study on Asthma Results Positive

                                  Boston Scientific Corporation (BSX) recently unveiled positive outcome from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study.

                                    Boston Scientific's Symetis Buyout Boosts Structural Heart

                                    Boston Scientific Corporation (BSX) recently completed the acquisition of Switzerland-based Symetis SA.

                                      Boston Scientific Hits a 52-Week High on Solid Prospects

                                      Share price of Natick, MA-based Boston Scientific Corporation (BSX) reached a new 52-week high of $26.76 on May 16, eventually closing a bit lower at $26.48.

                                        Boston Scientific (BSX) Misses on Q1 Earnings, Updates View

                                        Boston Scientific Corporation (BSX) posted adjusted EPS 29 cents in the first quarter, up 5.3% from the year-ago quarter.

                                          Boston Scientific (BSX): Beats on Q1 Sales, Misses Earnings

                                          Boston Scientific's adjusted earnings of 29 cents per share missed the Zacks Consensus Estimate in the first quarter.

                                            Will Boston Scientific (BSX) Surprise this Earnings Season?

                                            Boston Scientific Corporation (BSX) is scheduled to report first-quarter 2017 results before the opening bell on Apr 27.

                                              Boston Scientific's Emerging Markets Grow Amid Currency Woes

                                              On Apr 11 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

                                                Boston Scientific (BSX) Inks Agreement to Acquire Symetis SA

                                                Boston Scientific Corporation (BSX) recently signed a definitive agreement to acquire Switzerland-based Symetis SA for $435 million in up-front cash, in a bid to fortify its structural heart business in Europe.

                                                  Madeleine Johnson headshot

                                                  Obamacare Repeal Vote Looms: What Investors Need to Know

                                                  Investors' eyes will be focused on Congress today, as the House is scheduled to vote on the American Healthcare Act (AHCA). Whether you think it???s "Obamacare Lite" or "dead on arrival" like Sen. Rand Paul, the AHCA has certainly made an impact on Wall Street, as well as the entire healthcare industry since its announcement.